Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Mai 2026 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,...
15. Mai 2026 05:37 ET | Quelle: Research and Markets

APT-1011 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "APT-1011 Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The APT-1011 market report provides...
15. Mai 2026 05:33 ET | Quelle: Research and Markets

Tradipitant Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Tradipitant Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report offers insights into...
14. Mai 2026 09:45 ET | Quelle: Research and Markets

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
14. Mai 2026 09:26 ET | Quelle: Research and Markets

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Therapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
12. Mai 2026 11:46 ET | Quelle: Research and Markets

$16.8 Billion Targeted Cancer Therapy Market Report 2026-2031: Revenue to Grow by Nearly $10 Billion Over the Forecast Period

Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F" has been added to ResearchAndMarkets.com's...
07. Mai 2026 07:34 ET | Quelle: Research and Markets

IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "IgG4-Related Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
04. Mai 2026 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis

New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn., May ...
30. April 2026 12:19 ET | Quelle: Research and Markets

Contract Research and Manufacturing Services (CRAMS) Research Report 2026: $258.36 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 30, 2026 (GLOBE NEWSWIRE) -- The "Contract Research and Manufacturing Services (CRAMS) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Contract...
30. April 2026 07:05 ET | Quelle: AC Immune SA

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy...

Nächste Seite